Some Korea, Busan & Jeju
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Epidemiological Characteristics of Scab of Japanese Apricot in Korea
Plant Pathol. J. 33(5) : 450-457 (2017) https://doi.org/10.5423/PPJ.OA.03.2017.0044 The Plant Pathology Journal pISSN 1598-2254 eISSN 2093-9280 ©The Korean Society of Plant Pathology Research Article Open Access Epidemiological Characteristics of Scab of Japanese Apricot in Korea Gyoung Hee Kim1†, Kyoung Youn Jo1†, Jong Sup Shin2, Gil Ho Shin3, and Young Jin Koh1* 1Department of Plant Medicine, Sunchon National University, Suncheon 57922, Korea 2Suncheon City Agriculture Development and Technology Center, Suncheon 57908, Korea 3Jeonnam Agricultural Research and Extension Service, Naju 58213, Korea (Received on March 1, 2017; Revised on May 10, 2017; Accepted on May 23, 2017) Scabs caused by Venturia carpophila greatly reduce manage scabs of Japanese apricot in orchards. the quality of the fruits of the Japanese apricot (Prunus mume) when the disease is not properly managed. The Keywords : control, epidemiology, Japanese apricot, scab, disease produces a superficial blemish that is unlikely Venturia carpophila to affect the overall yield of processed fruit, but re- duce the value of fruit intended for the fresh market. Handling Associate Editor : Lee, Jungkwan Incidence rates of scab at sprayed and unsprayed or- chards range from 0% to 21.5% and from 30.2% to 100%, respectively, in the major cultivation regions of Japanese apricot (Prunus mume Sieb. Et Zucc.), which Jeonnam Province during the growing season of 2009. originates from central China, is a deciduous fruit-tree The trends in disease progress were quite similar, re- belonging to the rose family. The fruit of Japanese apricot gardless of regions, and cultivar Namgo was relatively has commonly been used as an ingredient in tea, cuisine, less damaged by scab compared to cultivar Cheonmae and herbal medicine for about 3,000 years in China, Ja- among the tested Japanese apricot cultivars. -
Korea Railroad Corporation
KOREA RAILROAD CORPORATION Issue of U.S.$ 150,000,000 Floating Rate Notes due 2024 (the “Notes”) Issued pursuant to the U.S.$2,000,000,000 Medium Term Note Program Issue Price: 100% of the Aggregate Nominal Amount Issue Date: November 29, 2019 This investor package includes (a) the offering circular dated August 28, 2018 relating to the U.S.$2,000,000,000 Medium Term Note Program (the “Program”) as supplemented by the pricing supplement dated November 18, 2019 relating to the Notes (the “Offering Circular”), and (b) this document dated November 29, 2019 as the cover page to the Offering Circular (the “Investor Package”). The Notes will be issued by Korea Railroad Corporation (the “Issuer”). Application will be made to the Taipei Exchange (the “TPEx”) for the listing of, and permission to deal in, the Notes by way of debt issues to professional investors as defined under Paragraph 1, Article 2-1 of the Taipei Exchange Rules Governing Management of Foreign Currency Denominated International Bonds of the ROC only and such permission is expected to become effective on or about November 29, 2019. TPEx is not responsible for the contents of this Investor Package and no representation is made by TPEx as to the accuracy or completeness of this Investor Package. TPEx expressly disclaims any and all liabilities for any losses arising from, or as a result of, the reliance on, all or part of the contents of this Investor Package. Admission for listing and trading of the Notes on the TPEx is not to be taken as an indication of the merits of the Issuer or the Notes. -
Nutrition and Obesity Prevention Source November 16-18, 2017, Barcelona, Spain Combination of Zonisamide and Weight Reduction Program in Obese Schizophrenic Patients
World Congress on Nutrition and Obesity Prevention Source November 16-18, 2017, Barcelona, Spain Combination of Zonisamide and Weight Reduction Program In Obese Schizophrenic Patients Jye Heon Song1, Bo-Hyun Yoon1, Gwang-Hun Lee2, Sang-Yeol Lee3, Moon-Doo Kim4, Jeong Seok Seo5, Jung Goo Lee6, Duk-In Jon7 and Wong-Myong Bahk8 1Department of Psychiatry, Naju National Mental Hospital, Naju, Korea 2Department of Psychiatry, College of Medicine, Dongkuk University, Gyeongju, Korea 3Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea 4Department of Psychiatry, Jeju National University School of Medicine, Jeju, Korea 5Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea 6Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea 7Department of Psychiatry, Hallym University College of Medicine, Anyang, Korea 8Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Objective: Obesity is one of the crucial risk factor for cardiometabolic syndrome in general population as well as in schizophrenic patients. Zonisamide was known for its weight reducing effect in the treatment of epileptic patients and some bipolar patients. The aim of this study was to investigate the weight reducing effect of zonisamide in combination with weight management program designed for schizophrenic inpatients. Method: One hundred twenty obese schizophrenic inpatients (BMI>27) were randomly assigned to 4 groups: A, control group (N=19), B, zonisamide alone group (N=34), C, weight reduction program alone group (N=32), and D, combination of zonisamide and weight reduction group (N=35). Daily dose of zonisamide was 100mg/day. -